Chimeric CypA Degrader Using PROTAC-Mediated Protein Breakdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective methods to target and degrade cyclophilin A (CypA) for addressing inflammation, autoimmune diseases, and tumors, as there are no reported CypA-targeted PROTAC drugs.
Innovation Solution
A chimeric compound is developed to specifically target and degrade CypA through a multi-step synthesis process, including hydrolysis, nucleophilic addition, reduction, nucleophilic substitution, deprotection, and amidation reactions, using specific solvents and reagents to optimize yield and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment methods are used, then existing therapies can be applied, but they cannot effectively target and degrade CypA protein
Solution Approach 1:
The PROTAC compound is divided into three functional moieties: a CypA-targeting ligand (Bix-0129), a flexible linker, and an E3 ubiquitin ligase ligand (Cereblon). This segmentation allows each component to perform its specific function independently while working together to achieve CypA degradation through the proteasome pathway.
Solution Approach 2:
The linker acts as an intermediary connecting the CypA-targeting ligand and the E3 ubiquitin ligase ligand. It provides spatial arrangement and flexibility to enable the formation of the productive complex that recruits CypA to the proteasome for degradation.
2Manufacturing precision
If a multi-step synthesis method is used, then compound purity and yield can be optimized, but the synthesis process becomes complex
Solution Approach 1:
The synthesis process is divided into seven discrete steps, each optimizing a specific aspect: (1) hydrolysis to form carboxylic acid, (2) nucleophilic addition to form hydroxyl group, (3) reduction to form alcohol, (4) nucleophilic substitution to introduce E3 ligase ligand, (5) another nucleophilic substitution to optimize connectivity, (6) deprotection to remove protecting groups, and (7) amidation to form final amide bond. This segmentation allows systematic optimization of each step's yield and purity.
Solution Approach 2:
The synthesis employs controlled parameter changes including temperature variations (0-100°C), pH adjustments through base treatment (step 1 and 5), and solvent selection (benzyl alcohol, methanol, DMF). These parameter changes optimize reaction conditions at each step to maximize purity and yield while managing complexity.
3Productivity
If the compound is designed to specifically target CypA, then degradation efficacy is improved, but selectivity and off-target effects become critical concerns
Solution Approach 1:
The compound exhibits local quality through its modular design where the Bix-0129 ligand specifically binds to CypA's hydrophobic pocket, while the Cereblon ligand specifically interacts with the E3 ubiquitin ligase. This localized specificity at different binding sites ensures high CypA degradation efficacy while maintaining overall selectivity to minimize off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively degrades CypA, alleviating inflammation, autoimmune diseases such as rheumatoid arthritis and psoriasis, and inhibiting tumor cell migration and infiltration, with minimal toxicity to cells.
Implementation Method 1
PROTAC (proteolysis-targeting chimera) consists of three moieties: a small-molecule ligand that recognizes the target protein, a linker and an E3 ubiquitin ligase ligand, and can directly degrade the target protein
Implementation Method 2
S1, subjecting a compound represented by Formula 1 to a hydrolysis reaction in the presence of a basic compound A to obtain a compound represented by Formula 2
Implementation Method 3
S2, subjecting the compound represented by Formula 2 to a nucleophilic addition reaction with a compound represented by Formula 3 to obtain a compound represented by Formula 4
Implementation Method 4
S3, reducing the compound represented by Formula 4 with palladium on carbon to obtain a compound represented by Formula 5
Implementation Method 5
S4, subjecting a compound represented by Formula 6 to a nucleophilic substitution reaction with a compound represented by Formula 7 in the presence of triethylamine and DMAP to obtain a compound represented by Formula 8
Implementation Method 6
S6, subjecting the compound represented by Formula 9 to a deprotection reaction in the presence of trifluoroacetic acid to obtain a compound represented by Formula 10
Implementation Method 7
S7, subjecting the compound represented by Formula 10 to an amidation reaction with a compound represented by Formula 11 in the presence of HOBT, EDCI and DIEA to obtain the compound represented by Formula I
Data Source
AI summary
Disclosed are a chimeric compound for degrading cyclophilin A, a preparation method therefor, and use thereof. The structural Formula of the chimeric compound is represented by Formula I. The compound represented by Formula I provided by the present invention can be used for preventing and/or treating CypA-mediated diseases, such as CypA-mediated inflammation, autoimmune diseases and/or tumors. The present invention further provides a pharmaceutical composition comprising the compound represented by Formula I as an active ingredient and at least one pharmaceutically acceptable carrier, excipient and/or diluent. The compound represented by Formula I provided by the present invention can target and degrade the CypA protein, and thus can be used for preparing a drug for treating inflammation, autoimmune diseases, tumors and other related diseases. The compound represented by Formula I of the present invention has the function of significantly inhibiting virus-induced pneumonia, rheumatoid arthritis and lung cancer cell migration and infiltration.